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Rat hepatocyte  protein kinase was activated by in- 
cubating  the cells with various cAMP analogs.  Boiled 
extracts were then  prepared  and  Sephadex G-25 chro- 
matography was carried  out.  The G-25 procedure sep- 
arated  the  analogs  from cAMP since the  resin had  the 
unexpected  property  of  binding cyclic nucleotides with 
differing affinities. Separation was necessary  because 
the  analogs  would otherwise interfere with the sensi- 
tive protein kinase activation method developed for 
assay of  CAMP.  The  cAMP analogs,  but  not  S‘-AMP, 
lowered  basal cAMP  by 50-70%. The effect was rapid, 
analog  concentration-dependent,  and  occurred  parallel 
with phosphorylase activation, suggesting that  the 
cAMP analogs act through CAMP-dependent protein 
kinase activation. A cAMP analog  completely  blocked 
the cAMP elevation produced  by relatively low  concen- 
trations  of  glucagon,  but  did  not  block  the  phosphoryl- 
ase response,  indicating  that  the cAMP analog  substi- 
tutes  for cAMP as the  intracellular  activator of  protein 
kinase. One implication of  the results is that elevation 
of  cAMP  and protein kinase activity by  hormones  has 
a negative feedback effect on the  cellular cAMP level. 
~ ~ ~~ ~ 
There  are  present  in biological systems certain processes 
which amplify hormonal effects. A few molecules of glucagon, 
for example, can cause thousands of glucose  molecules to be 
produced in liver. However, in order for such amplification to 
be effective, each step involved must not be excessive. For 
example, changes in cellular cAMP levels usually occur within 
a very narrow concentration range, physiological processes 
being maximally stimulated by increases in cAMP of only 2- 
3-fold (1-3). If the cAMP concentration were to be elevated 
to very high levels relative to  the physiological range, reversal 
of the stimulatory processes would be difficult. In order that 
such excessive changes do not occur, “leak” systems are also 
present for dampening the amplification (4). Phosphodiester- 
ases and protein  phosphatases  are two types of leak systems 
in the reactions of the cAMP cascade. These enzyme activities 
are increased because of increases in substrate levels. They 
serve, on the one hand, to dampen the increase in CAMP, 
and,  on the  other hand, to dephosphorylate, or deactivate, the 
protein phosphorylation reactions. Cells have also evolved 
mechanisms to “desensitize,” “down-regulate,” or produce 
“refractoriness” after chronic exposure to hormones which 
elevate cAMP (1, 5-8). These  in some cases involve uncou- 
pling of the hormone receptor from the adenylate cyclase. In 
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addition to long-term desensitization effects, there may exist 
feedback mechanisms for acutely dampening the hormonal 
effect on cAMP levels. A convenient route of such control 
would  be through activation of CAMP-dependent protein ki- 
nase, which thus far  has been the only receptor for cAMP 
shown to be present in higher eukaryotes. It would  be difficult 
to study a dampening effect of kinase activation on cAMP 
levels by the use of hormones. However, such a study can be 
accomplished by using cAMP analogs to bypass the hormone- 
adenylate cyclase steps. Analogs of cAMP are known to enter 
cells and specifically activate CAMP-dependent protein kinase 
(9). This report presents a simple method for carrying out 
purification and assay of cAMP after  treatment of hepato- 
cytes with cAMP analogs. Using phosphorylase activation as 
an indicator of protein kinase activation, it is shown that 
intracellular  stimulation of the kinase dampens the hormonal 
elevation of cAMP in hepatocytes. 
METHODS 
Preparation and Incubation of Hepatocytes-Hepatocytes from 
male Sprague-Dawley rats (200-250 g of  body weight) were prepared 
as previously described (10). Cyclic AMP analogs were added to cell 
suspensions (-50 mg  of cells/ml) in 25-ml Erlenmeyer flasks a t  37 “C 
which were continuously gassed with 02:COz (191). At various times 
aliquots were removed for the measurement of phosphorylase or 
CAMP. All cAMP analog stock solutions were 100-fold more concen- 
trated  than  the desired final concentration in the hepatocyte suspen- 
sions. 
Preparation of Extracts and Assay of Phosphorylase-At the  end of 
the hepatocyte incubations, 500-pl aliquots of the cell suspensions 
were  removed, immediately frozen in liquid nitrogen, and stored at 
-20 “C. The pellets were thawed at room temperature for 10 min. 
One ml of homogenizing buffer containing 150 mM 8-glycerophos- 
phate, 30 mM EDTA, 150 mM NaF, 600 mM sucrose, and 6.5 mg/ml 
L-cysteine was added, and  the suspension was  homogenized  for 10 s 
using an Ultraturrex  TissuemizeP. Homogenates were immediately 
assayed for phosphorylase activity in the absence of 5’-AMP (10). 
Preparation of Boiled Extracts for Sephadex (3-25 Purification of 
CAMP-Four ml  of cell suspension was centrifuged at 500 X g, the 
supernatant was removed, and  the cell pellet was frozen in liquid 
nitrogen and stored at -70  ‘C. Frozen cell pellets were  removed from 
-70 “C  and thawed at room temperature for 3-5 min. One ml  of ice- 
cold homogenizing buffer (25 mM NH,HCOs, pH 7.8,l mM 3-isobutyl- 
1-methylxanthine, and 20 mM EDTA) was added, and the suspension 
was placed on ice. The partially thawed pellets were  homogenized for 
10 s using an Ultraturrex Tissuemizer@. The  entire homogenate was 
placed in a 1.5-ml microfhge tube and placed in a boiling water bath 
for 5 min. The boiled homogenates were centrifuged for 7 min in a 
Beckman Microfuge B. The boiled extract was carefully removed and 
chilled on ice  before purification of cAMP by Sephadex G-25 chro- 
matography of 0.5-ml aliquots as described under “Results.” 
Assay of  CAMP-The type I CAMP-dependent protein kinase used 
for the assay was purified from rabbit skeletal muscle through the 
DEAE-cellulose step (11). The enzyme was frozen and stored at 
-70 “C in small aliquots which  were thawed immediately before use 
by hand-warming. Protein kinase assays were performed at different 
times and temperatures as shown in Fig. 3. To 20 pl of reaction 
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mixture containing 40 mM Tris-HC1, pH 7.4, 0.1 mM 3-isobutyl-l- 
methylxanthine, 130 p~ heptapeptide  (Kemptide), 20 mM magnesium 
acetate, and 0.2 mM [32P]ATP (-100 cpm/pmol) was added 60 pl of 
fractions from the Sephadex G-25 chromatography or cAMP stand- 
ards diluted in the same 50 mM NHIHC03, pH 7.8. Reactions were 
initiated with 20 pl of enzyme diluted to 0.33 nM with 10 mM 
potassium phosphate, pH 6.8, 1 mM EDTA, and 1 mg/ml bovine 
serum albumin. After incubation, 50-p1 aliquots of the mixture were 
spotted on phosphocellulose papers which were washed in 75 mM 
phosphoric acid according to Roskoski (12). 
In one  experiment  cAMP was also assayed by radioimmunoassay 
Purification of CAMP Analogs-The cAMP analogs which were 
used for cell incubations were first chromatographed on  a 0.9 X 57- 
cm Sephadex G-25 (superfine) column as described in the legend to 
Fig. 1. The  total volume (V,) of the G-25 was taken  as  the elution 
volume of r3HlH20.  The elution volume of a  particular  substance was 
(13-15). 
. I -  
denoted as V.. 
Materials-The heDtaDeDtide substrate, Leu-Arg-Arg-Ala-Ser- 
LeuIGly, was from Peninsula Laboratories. Sephadex G-25 (super- 
fine) and gel filtration columns were purchased from Pharmacia. 
cAMP and cAMP analogs were from Sigma, and [3H]cAMP was from 
New England Nuclear. 8-pC1@S-cGMP1 was synthesized by the 
method of Miller et al. (16). [Y-~'P]ATP was prepared by the method 
of Walseth and Johnson (17). Glucagon was a gift from Eli Lilly. 
- " 
RESULTS 
Sephadex G-25 Chromatography of Cyclic Nucleotides- 
Since most cyclic nucleotide analogs are known to interfere 
in biospecific assays or radioimmunoassays of cAMP (13-15, 
18),  it was necessary to devise a method for separating the 
analog from cAMP before assay. Various nucleotides are 
known to bind to Sephadex columns with different affinities 
(19). Many have elution volumes (V,) greater than  the  total 
volume (V,) of the columns. The Sephadex G-25 (superfine) 
elution profiles for several cyclic nucleotides are shown in Fig. 
1. Of the four nucleotides chromatographed, only N6-butyryl- 
cAMP  eluted at less than  the  total volume as determined by 
[3H]H20 elution. It can be seen that all  three analogs were 
clearly separated from cAMP at  this temperature (20 "C). It 
was found subsequently that even better  separation could be 
obtained at 4 "C. For example, cAMP and cGMP were poorly 
separated at 20 "C, but were almost completely separated at  
4 "C. The elution volume of [3H]H20 (V,) was not different 
at  the different temperatures, but  the VJV,  of cAMP changed 
from 1.35 at  20 "C to 1.62 at 4 "C. The relatively long column 
(0.9 x 57 cm) used for the experiment of Fig. 1 allowed for 
high resolution of cyclic nucleotides, but a shorter column 
(0.9 x 14 cm) at 4 "C was sufficient to separate most of the 
analogs and allowed for rapid (-2 h) processing of boiled 
hepatocyte extracts. Chromatography of a boiled hepatocyte 
extract on the  short column at 4 "C is shown in Fig. 2. It can 
be seen that 8-pCldS-cAMP separated well from CAMP. It 
can also be seen that cAMP was separated from almost all of 
the absorbing material of the extract. The assayable 
cAMP of the  extract coeluted with the trace  amount of [3H] 
cAMP added to  the extract. The small 3H peak preceding the 
[3H]cAMP peak could represent [3H]H20, since the V, was 
identical to  that of [3H]H20 chromatographed in a different 
run. The method of Fig. 2 was adopted for almost all of the 
experiments, although the longer column was necessary for 
separating some analogs which had  a V, nearly the same as 
that of CAMP. 
Assay of CAMP by Protein Kinase Activation-Because of 
the dilution which resulted from the Sephadex chromatogra- 
phy, it was necessary to develop a sensitive assay for CAMP. 
The use of protein kinase activation at 30 "C was reported 
previously (20). It can be seen in Fig. 3 that  the kinase was 
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FIG. 1. Chromatography of cAMP analogs on Sephadex G- 
26. Samples (0.5  ml of 100 mM N'-butyryl-cAMP, 0.3 mM 8-pClgS- 
CAMP, 20 mM 8-Br-cAMP, or 0.1  ml of 1 mM CAMP) were  dissolved 
in HzO and -60 mg  of sucrose was added to each and dissolved. They 
were then applied at  20  "C to a 0.9 X 57-cm Sephadex G-25 (superfine) 
column which had been equilibrated in 50 mM NH4HC03, pH 7.8. 
Collection was by gravity flow with 60 cm of hydrostatic pressure. 
diluted 700-fold and 8-Br-CAMP samples were diluted 100-fold before 
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FIG. 2. Chromatography of a  crude hepatocyte extract on 
Sephadex G-26. The hepatocyte extract was prepared as described 
under "Methods." Ten pl of 1.8 X lo" M [3H]cAMP (80,000 cpm) 
was added at  4 "C to 0.5 ml of extract. Solid sucrose (-60 mg)  was 
then added and dissolved, and  the sample was applied at  4 "C to a 0.9 
X 14-cm Sephadex G-25 (superfine) column equilibrated in 50 mM 
NH4HC03, pH 7.8. One-ml fractions were collected by gravity flow 
(50 cm of hydrostatic pressure). Fifty-pl aliquots were analyzed for 
radioactivity. Sixty-pl aliquots were used for cAMP determination as 
described under "Methods," and  the Ezso was measured spectropho- 
tometrically. The elution of 60 p~ 8-pCl@S-cAMP was determined in 
a  separate chromatographic run performed identically and  the profile 
is shown for comparison. The presence of the extract did not signifi- 
cantly  alter the elution of &pCl@S-cAMP (not shown). 
much more sensitive to cAMP at 0 "C than  at higher temper- 
atures, presumably because the affinity of cAMP binding 
increased. The K, obtained at 0 "C (5 nM) was 16 times lower 
than  that  at 30  "C. In order to produce sufficient 32P-hepta- 
peptide at lower temperatures, it was necessary to incubate 
the reaction for longer times, an overnight incubation at 0 "C 
being convenient. The type I isozyme of rabbit skeletal muscle 
was used for the experiments reported here because it was 
found to be more sensitive to cAMP than was the bovine 
heart type I1 isozyme under the conditions used. It can be 
seen in Fig. 4 that  the cAMP level determined using the G- 
25 fractions of hepatocyte extracts was similar whether per- 
formed by protein kinase activation assays or radioimmu- 
noassays. 
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FIG. 3. Assay  of cAMP  by protein kinase activation at dif- 
ferent  temperatures. The enzyme used was the type I isozyme of 
rabbit skeletal muscle. The temperature and times of incubation with 
various cAMP concentrations  are indicated. Heptapeptide was used 
as substrate.  Other conditions are  stated under “Methods.” 
I t  
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MINUTES OF HEPATOCYTE INCUBATION 
FIG. 4. Effect of  incubation  time  on  S-pCl@S-cAMP  lower- 
ing of  hepatocyte  CAMP levels and activation  of  phosphoryl- 
ase. Hepatocytes were incubated with 1 p~ S-pCl@S-cAMP for the 
indicated times. Extracts were prepared and processed as described 
under “Methods.” cAMP was assayed by radioimmunoassay (RIA) 
and by protein kinase activation (PKA) as indicated. 
Effect of CAMP Analogs on Basal Hepatocyte CAMP-In 
order to ensure the absence of trace  contamination of analogs 
by CAMP, the analogs were first purified on Sephadex G-25 
columns before use in cell incubations. If purified 1 PM 
8-pCldS-CAMP was added at  zero time to hepatocytes, the 
cAMP level fell by more than 50% (Fig. 4). The effect occurred 
in 3 min or less, and  the cAMP level  was found to be lowered 
using both  types of cAMP assays. Activation of phosphorylase 
occurred parallel with the lowering of CAMP. This result 
suggested that the intracellular concentration of 8-pCldS- 
cAMP was sufficient to activate CAMP-dependent protein 
kinase, ultimately causing phosphorylase activation. The ef- 
fect of 8-pCldS-cAMP to lower hepatocyte cAMP was analog 
concentration-dependent. It can be seen in Fig. 5 that concen- 
trations of 0.25 pM or higher of the analog were effective in 
lowering CAMP. The correlation between the lowering of 
cAMP  and phosphorylase activation was  good, except at 0.1 
p M  analog, where maximal phosphorylase activity was seen 
P 
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FIG. 5. Effect of 8-pCl@S-cAMP concentration on cAMP 
level and  phosphorylase. activity in  hepatocytes. Hepatocytes 
were incubated for 5 min with the indicated concentrations of 8- 
pCl@S-CAMP. Extracts were prepared and processed as described 
under “Methods.” G-1 -P, glucose 1-phosphate. 
with only a slight change in CAMP. It is known, however, that 
small increases in  intracellular kinase activity are sufficient 
to cause maximal phosphorylase activation in hepatocytes 
(21). The CAMP-lowering effect was also seen with several 
cyclic nucleotide analogs other  than 8-pCldS-cAMP (Table I, 
Experiments 1 and 2) but  not with 5’-AMP (Table I, Exper- 
iment 3). A cGMP analog, 8-pCldS-cGMP, also caused low- 
ering of CAMP, but  it  is known that cGMP analogs stimulate 
cAMP processes in hepatocytes (22). The lowering of cAMP 
obtained with cyclic nucleotide analogs was associated in each 
case with an activation of phosphorylase. 
Effect of CAMP Analogs and Glucagon on Hepatocyte 
CAMP-The CAMP-lowering effect of 8-pCldS-cAMP was 
also obtained when hepatocytes were incubated with relatively 
low glucagon concentrations. It can be seen in  Table  I (Ex- 
periment 4) that 0.1 or 0.2 nM glucagon treatment elevated 
cAMP appreciably. These effects were completely blocked or 
nearly completely blocked, respectively, by the addition of 8- 
pCl#S-CAMP. However, when 100 nM glucagon was used 
(Table I, Experiment 3)) which generated very  high cellular 
CAMP, the analog did not block the effect. A time course for 
the effect of 0.1 nM glucagon in the absence and presence of 
8-pC1dS-CAMP is shown in Fig. 6. It can be seen that  the 
glucagon-induced elevation in cAMP was transient,  the level 
rapidly increasing during the  first 5 min and  then declining 
toward the basal value by 10 min. The glucagon-induced 
elevation in cAMP did not occur  when  8-pC14S-CAMP  was 
present. Glucagon caused phosphorylase activation regardless 
of whether or not the cAMP analog was present. In the 
absence of analog, the phosphorylase activity declined slightly 
after 5 min of incubation. 
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TABLE I
Effects of CAMP amlogs and glucagon on hepatocyte CAMP levels 
Hepatocytes were incubated for 5 min. One PM cAMP analogs were added. Except where indicated, values are 
means of duplicate cell incubations. AHCM-, aminohexylcarbamoylmethyl-; G-1-P, glucose 1-phosphate. 
Experiment Addition cAMP Phosphorylase 
nrnollg tissue pmol G-I-Pfgfmin 
0.37 f 0.05 ( n  = 3) 21.3 
0.33 f 0.08 ( n  = 3) 17.5 
0.44 f 0.08 ( n  = 3) 11.5 
















3 0 0.22 
5”AMP 0.23 
100 nM glucagon  5.03 
100 nM glucagon + 8-pCl@S-cAMP 5.77 
4 0 0.33 
8-pCl@S-cAMP 0.19 
0.1 nM glucagon 0.95 
0.1 nM glucagon + 8-pCI@S-cAMP 0.32 
0.2 nM glucagon 1.18 
0.2 nM glucagon + 8-pCl@S-cAMP 0.59 
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FIG. 6. Effect  of 0.1 n M  glucagon  in  the  absence  and  pres- 
ence of 1 p~ S-pClbS-cAMP  on  hepatocyte  cAMP  and  phos- 
phorylase. Extracts were prepared and processed as described under 
“Methods.” 
DISCUSSION 
To our knowledge, the results  presented here are  the first 
reported evidence for control of the hepatocyte cAMP level 
through  protein kinase activation. This type of control might 
be considered as negative feedback and could  be beneficial to 
the cell by preventing excessive cAMP accumulation. It is 
known that cAMP fluctuates over a narrow concentration 
range in most cell types. If the effect is found to occur with 
any hormone which elevates cAMP it would  be classified as a 
heterologous type of desensitization (6). The transient in- 
crease in cAMP by glucagon observed here could be taken  as 
one line of evidence for a desensitization produced by cAMP 
elevation. It has since been found that readdition of glucagon, 
after the fall in CAMP, produces a smaller rise in cAMP than 
the original (results  not shown). 
It will be of interest to determine if the CAMP-lowering 
effect of cAMP analogs is  present  in cell types other  than 
hepatocytes. Mulner et al. (23) recently reported that microin- 
jection of protein kinase inhibitor  into Xenopus oocytes causes 
an increase in CAMP, which is consistent with our findings. 
Fisher et al. (24) observed a rapid (2-3 min) desensitization 
of 8-adrenergic stimulation of heart cells,  which is quantita- 
tively related to cellular CAMP. A CAMP-mediated desensi- 
tization was also suggested by the finding of Barovsky et al. 
(25) that  pretreatment of glioma cells with a cAMP analog 
produces refractoriness toward forskolin. 
The mechanism for the lowering of cAMP by cAMP analogs 
is  not clear, although it seems reasonable to assume that  it 
occurs through protein kinase activation. The results of a 
recent comprehensive study of cAMP analog effects on lipol- 
ysis and glycogenolysis in adipocytes and hepatocytes, respec- 
tively, indicated that  the analogs are  acting by directly stim- 
ulating CAMP-dependent protein kinase (9). If protein phos- 
phorylation is involved, then  the target  protein(s) could be 
part of either the adenylate cyclase  complex or the phospho- 
diesterase. Presumably /+receptor phosphorylation is not  in- 
volved since the cAMP analog effects are obtained in the 
basal state or in the presence of glucagon. Of course, there 
may exist cAMP regulation of components of adenylate cy- 
clase other than the @receptor. Several groups have also 
reported that a hormone-sensitive, low K,  phosphodiesterase 
is activated in adipose tissue (26, 27) and  in liver (28-30) by 
addition  either of hormones which elevate cAMP or of cAMP 
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analogs. Since the CAMP-dependent protein kinase is the 
only known mediator of cAMP effects in mammalian tissues, 
it is reasoned that  this enzyme is responsible for these effects. 
One group has  reported that  the low K,,, phosphodiesterase 
can be phosphorylated by the protein kinase (30). Paradoxi- 
cally, insulin also activates the same phosphodiesterase even 
though this hormone is known to lower cAMP in these  tissues 
(1, 2, 26-30). Other phosphodiesterases cannot be ruled out 
as targets of the cAMP effect. For example, cAMP analogs 
could cause an elevation in cellular calcium ion which could 
activate  a calmodulin-sensitive phosphodiesterase (31). There 
are also known to be present cGMP-binding phosphodiester- 
ases (32). It has been suggested, however, that phosphodies- 
terases  are  not the likely target enzymes involved in desensi- 
tization processes (7). 
Another explanation for the results which should be con- 
sidered is that  the cAMP analogs could compete with endog- 
enous cAMP for the binding sites on the protein kinase. Thus, 
activation of the kinase by the analogs might occur parallel 
with an increase in free CAMP. Since free CAMP, but not 
bound CAMP, is a  substrate for phosphodiesterase (33), the 
cAMP level could be lowered simply because of higher sub- 
strate availability. It might be difficult to distinguish between 
this mechanism and a  protein phosphorylation reaction since 
an increase in free cAMP due to analog competition would  be 
expected to occur in  direct parallel with protein kinase acti- 
vation. 
Perhaps  the cAMP analog effects are tissue-specific since 
Jarett  and  Smith (34) found that adipocyte cAMP levels are 
actually increased by the addition of N6,02' -&butyryl CAMP. 
It was suggested that  the increase in cAMP is brought about 
by inhibition of phosphodiesterase through competition be- 
tween the analog and endogenous CAMP. This explanation 
for cAMP analog effects has been a  dominant viewpoint for 
many years. I t  would  be surprising, however, if the effects of 
most cAMP analogs on physiological responses are mediated 
through rises in cellular cAMP caused by competitive inhibi- 
tion of phosphodiesterase. In general, the analogs have much 
higher affinities for the protein kinase than for the phospho- 
diesterase (9). At  rate-limiting  concentrations of analogs, it 
would be much more likely that they are acting through 
protein kinase activation than through phosphodiesterase 
inhibition.  In fact, the results  presented here indicate that in 
hepatocytes the analogs cause a decrease, rather than an 
increase, in cellular CAMP. 
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